SV

Srinivas Vadepalli

Active Director Director DIN 10770875
DIN 10770875 First appointment Sep 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2024
Shareholding value •••• Premium profile

About Srinivas Vadepalli

Data last updated:

Srinivas Vadepalli is a Director at Sunventies Pharmaceuticals Private Limited (since 2024). The company operates in Pharma. Sunventies Pharmaceuticals Private Limited reported revenue of ₹9.9 Lakh (FY 2025).

DIN 10770875
Primary Designation Director
Industry Pharma
First Appointment 07 Sep 2024
Oldest Company Age 3 yrs
Largest company Sunventies Pharmaceuticals Private Limited · ₹9.9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director07 Sep 20242023₹9.9 Lakh (FY 2025)Active

Board colleagues of Srinivas Vadepalli

Directorship timeline

Open interactive timeline →
Sunventies Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Srinivas Vadepalli

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Srinivas Vadepalli

Srinivas Vadepalli currently holds 1 directorship: Sunventies Pharmaceuticals Private Limited (Director, since 07 Sep 2024, revenue ₹9.9 Lakh (FY 2025)).

Srinivas Vadepalli was first appointed on 07 Sep 2024 as Director at Sunventies Pharmaceuticals Private Limited.

The current boards of Srinivas Vadepalli's companies include Vadepalli Shiva Praveen (Sunventies Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available